select a format

Single User License
USD 250 INR 16280
Site License
USD 500 INR 32560
Corporate User License
USD 750 INR 48840

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Debiopharm Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Debiopharm Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH1154631D
  • |
  • Pages: 49
  • |
  • July 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Debiopharm Group (Debiopharm) is a developer of biologics and small molecule drug candidates targeted at unmet medical needs. The company's products portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory services and innovative drug delivery and formulation, among others. Debiopharm targets therapy areas including colorectal cancer, ovarian cancer, breast cancer, prostate cancer and other sexual disorders, among others. The company has presence in Switzerland and Canada. Debiopharm is headquartered in Lausanne, Switzerland.

Debiopharm Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Debiopharm Group, Medical Devices Deals, 2011 to YTD 2017 10

Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Debiopharm Group, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14

Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15

Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16

Venture Financing 17

Immunexpress Raises USD6 Million In Venture Financing 17

Biocartis Raises USD40.5 Million In Series E Financing 18

Spinomix Raises USD3 Million In Series A Financing 20

Biocartis Raises USD44.7 Million In Series D Financing 20

Biocartis Secures USD96 Million In Series C Financing Round 22

Partnerships 24

Debiopharm Partners with Merck and Pfizer 24

Debiopharm Enters into Distribution Agreement with Arbor Pharma 25

Debiopharm International Enters into Agreement with EORTC 26

United Labs Enters into Distribution Agreement with Debiopharm International 26

Debiopharm Enters into Agreement with Solid Biosciences 27

Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 28

Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 29

Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 30

Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 31

Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 32

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32

Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33

Licensing Agreements 34

Debiopharm International Enters into Licensing Agreement with Almac Discovery 34

Debiopharm Enters Into Licensing Agreement With Yale University 35

Evotec Enters Into Licensing Agreement With Debiopharm 36

Shasun Pharma Enters Into Licensing Agreement With Debiopharm 37

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 38

Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 39

Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 40

Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 41

Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 42

Equity Offering 43

Neovacs Completes Private Placement of Shares For USD3.2 Million 43

Acquisition 44

Debiopharm To Acquire Pharma Company 44

Debiopharm Group-Key Competitors 46

Key Employees 47

Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Debiopharm Group, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Debiopharm Group, Pharmaceuticals & Healthcare, Key Facts 1

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Debiopharm Group, Deals By Therapy Area, 2011 to YTD 2017 9

Debiopharm Group, Medical Devices Deals, 2011 to YTD 2017 10

Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 14

Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 15

Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 16

Immunexpress Raises USD6 Million In Venture Financing 17

Biocartis Raises USD40.5 Million In Series E Financing 18

Spinomix Raises USD3 Million In Series A Financing 20

Biocartis Raises USD44.7 Million In Series D Financing 20

Biocartis Secures USD96 Million In Series C Financing Round 22

Debiopharm Partners with Merck and Pfizer 24

Debiopharm Enters into Distribution Agreement with Arbor Pharma 25

Debiopharm International Enters into Agreement with EORTC 26

United Labs Enters into Distribution Agreement with Debiopharm International 26

Debiopharm Enters into Agreement with Solid Biosciences 27

Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 28

Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 29

Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 30

Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 31

Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 32

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 32

Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 33

Debiopharm International Enters into Licensing Agreement with Almac Discovery 34

Debiopharm Enters Into Licensing Agreement With Yale University 35

Evotec Enters Into Licensing Agreement With Debiopharm 36

Shasun Pharma Enters Into Licensing Agreement With Debiopharm 37

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 38

Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 39

Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 40

Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 41

Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 42

Neovacs Completes Private Placement of Shares For USD3.2 Million 43

Debiopharm To Acquire Pharma Company 44

Debiopharm Group, Key Competitors 46

Debiopharm Group, Key Employees 47

Debiopharm Group, Subsidiaries 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Debiopharm Group, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com